Novel theranostic agents for next-generation personalized medicine: Small molecules, nanoparticles, and engineered mammalian cells

Current Opinion in Chemical Biology

Volumn 28, Issue , 2015, Pages 29-38

  Kojima, Ryosuke ^a   Aubel, Dominique ^b   Fussenegger, Martin ^a,c  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOTIN; FOLIC ACID; NANOPARTICLE; PHOTOSENSITIZING AGENT; PRAMLINTIDE; PRODRUG; REAGENT; THERANOSTIC REAGENT; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; MOLECULAR LIBRARY;

BIOLOGY; BIOSENSOR; CONJUGATE; HUMAN; INFORMATION; MAMMAL CELL; MATERIALS; MOLECULE; NEOPLASM; NONHUMAN; PERSONALIZED MEDICINE; REVIEW; SCIENCE; SYNTHETIC BIOLOGY; ANIMAL; BIOLOGICAL THERAPY; CHEMISTRY; GENETIC ENGINEERING; MOLECULAR LIBRARY; PROCEDURES; THERANOSTIC NANOMEDICINE; THERAPEUTIC USE;

MAMMALIA;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; GENETIC ENGINEERING; HUMANS; IMMUNOCONJUGATES; NANOPARTICLES; PRECISION MEDICINE; SMALL MOLECULE LIBRARIES; THERANOSTIC NANOMEDICINE;

EID: 84930633785     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2015.05.021     Document Type: Review

References (66)

1. Hood E. Pharmacogenomics: the promise of personalized medicine. Environ Health Perspect 2003, 111:A581-A589.
2. Shah R.R., Shah D.R. Personalized medicine: is it a pharmacogenetic mirage?. Br J Clin Pharmacol 2012, 74:698-721.
3. Crawley N., Thompson M., Romaschin A. Theranostics in the growing field of personalized medicine: an analytical chemistry perspective. Anal Chem 2014, 86:130-160.
4. Kelkar S.S., Reineke T.M. Theranostics: combining imaging and therapy. Bioconjugate Chem 2011, 22:1879-1903.
5. Jeelani S., Reddy R.C., Maheswaran T., Asokan G.S., Dany A., Anand B. Theranostics A treasured tailor for tomorrow. J Pharm Bioallied Sci 2014, 6:S6-S8.
6. Svenson S. Theranostics are we there yet?. Mol Pharm 2013, 10:848-856.
7. Meric-Bernstam F., Mills G.B. Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol 2012, 9:542-548.
8. Yang Z., Lee J.H., Jeon H.M., Han J.H., Park N., He Y., Lee H., Hong K.S., Kang C., Kim J.S. Folate-based near-infrared fluorescent theranostic gemcitabine delivery. J Am Chem Soc 2013, 135:11657-11662.
9. Yuan Y., Kwok R.T., Tang B.Z., Liu B. Targeted theranostic platinum(IV) prodrug with a built-in aggregation-induced emission light-up apoptosis sensor for noninvasive early evaluation of its therapeutic responses in situ. J Am Chem Soc 2014, 136:2546-2554.
10. Bhuniya S., Maiti S., Kim E.J., Lee H., Sessler J.L., Hong K.S., Kim J.S. An activatable theranostic for targeted cancer therapy and imaging. Angew Chem Int Ed Engl 2014, 53:4469-4474.
11. Maiti S., Park N., Han J.H., Jeon H.M., Lee J.H., Bhuniya S., Kang C., Kim J.S. Gemcitabine-coumarin-biotin conjugates: a target specific theranostic anticancer prodrug. J Am Chem Soc 2013, 135:4567-4572.
12. He H., Lo P.C., Ng D.K. A glutathione-activated phthalocyanine-based photosensitizer for photodynamic therapy. Chem Eur J 2014, 20:6241-6245.
13. Mitsunaga M., Ogawa M., Kosaka N., Rosenblum L.T., Choyke P.L., Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med 2011, 17:1685-1691.
14. Spring B.Q., Abu-Yousif A.O., Palanisami A., Rizvi I., Zheng X., Mai Z., Anbil S., Sears R.B., Mensah L.B., Goldschmidt R., et al. Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates. Proc Natl Acad Sci U S A 2014, 111:E933-E942.
15. Lukianova-Hleb E.Y., Ren X., Sawant R.R., Wu X., Torchilin V.P., Lapotko D.O. On-demand intracellular amplification of chemoradiation with cancer-specific plasmonic nanobubbles. Nat Med 2014, 20:778-784.
16. Li Y.P., Lin T.Y., Luo Y., Liu Q.Q., Xiao W.W., Guo W.C., Lac D., Zhang H.Y., Feng C.H., Wachsmann-Hogiu S., et al. A smart and versatile theranostic nanomedicine platform based on nanoporphyrin. Nat Commun 2014, 5:4712. 10.1038/ncomms5712.
17. Tian J., Ding L., Ju H., Yang Y., Li X., Shen Z., Zhu Z., Yu J.S., Yang C.J. A multifunctional nanomicelle for real-time targeted imaging and precise near-infrared cancer therapy. Angew Chem Int Ed Engl 2014, 53:9544-9549.
18. Tian J., Ding L., Xu H.J., Shen Z., Ju H., Jia L., Bao L., Yu J.S. Cell-specific and pH-activatable rubyrin-loaded nanoparticles for highly selective near-infrared photodynamic therapy against cancer. J Am Chem Soc 2013, 135:18850-18858.
19. Wu X., Sun X., Guo Z., Tang J., Shen Y., James T.D., Tian H., Zhu W. In vivo and in situ tracking cancer chemotherapy by highly photostable NIR fluorescent theranostic prodrug. J Am Chem Soc 2014, 136:3579-3588.
20. Ansari C., Tikhomirov G.A., Hong S.H., Falconer R.A., Loadman P.M., Gill J.H., Castaneda R., Hazard F.K., Tong L., Lenkov O.D., et al. Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. Small 2014, 10. 566-575, 417.
21. Song J., Zhou J., Duan H. Self-assembled plasmonic vesicles of SERS-encoded amphiphilic gold nanoparticles for cancer cell targeting and traceable intracellular drug delivery. J Am Chem Soc 2012, 134:13458-13469.
22. Shrestha R., Elsabahy M., Luehmann H., Samarajeewa S., Florez-Malaver S., Lee N.S., Welch M.J., Liu Y.J., Wooley K.L. Hierarchically assembled theranostic nanostructures for siRNA delivery and imaging applications. J Am Chem Soc 2012, 134:17362-17365.
23. Delogu L.G., Vidili G., Venturelli E., Menard-Moyon C., Zoroddu M.A., Pilo G., Nicolussi P., Ligios C., Bedognetti D., Sgarrella F., et al. Functionalized multiwalled carbon nanotubes as ultrasound contrast agents. Proc Natl Acad Sci U S A 2012, 109:16612-16617.
24. Huang P., Lin J., Li W., Rong P., Wang Z., Wang S., Wang X., Sun X., Aronova M., Niu G., et al. Biodegradable gold nanovesicles with an ultrastrong plasmonic coupling effect for photoacoustic imaging and photothermal therapy. Angew Chem Int Ed Engl 2013, 52:13958-13964.
25. McCarthy J.R., Jaffer F.A., Weissleder R. A macrophage-targeted theranostic nanoparticle for biomedical applications. Small 2006, 2:983-987.
26. McCarthy J.R., Korngold E., Weissleder R., Jaffer F.A. A light-activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. Small 2010, 6:2041-2049.
27. Lobatto M.E., Fuster V., Fayad Z.A., Mulder W.J.M. Perspectives and opportunities for nanomedicine in the management of atherosclerosis (vol. 10, p. 835, 2011). Nat Rev Drug Discov 2011, 10:963.
28. Kim H., Kim Y., Kim I.H., Kim K., Choi Y. ROS-responsive activatable photosensitizing agent for imaging and photodynamic therapy of activated macrophages. Theranostics 2014, 4:1-11.
29. Wang P., Yigit M.V., Ran C., Ross A., Wei L., Dai G., Medarova Z., Moore A. A theranostic small interfering RNA nanoprobe protects pancreatic islet grafts from adoptively transferred immune rejection. Diabetes 2012, 61:3247-3254.
30. Barrett D.M., Singh N., Porter D.L., Grupp S.A., June C.H. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014, 65:333-347.
31. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., Teachey D.T., Chew A., Hauck B., Wright J.F., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013, 368:1509-1518.
32. Lanitis E., Poussin M., Klattenhoff A.W., Song D., Sandaltzopoulos R., June C.H., Powell D.J. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res 2013, 1:43-53.
33. Kloss C.C., Condomines M., Cartellieri M., Bachmann M., Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013, 31:71-75.
34. Wei P., Wong W.W., Park J.S., Corcoran E.E., Peisajovich S.G., Onuffer J.J., Weiss A., Lim W.A. Bacterial virulence proteins as tools to rewire kinase pathways in yeast and immune cells. Nature 2012, 488:384-388.
35. Park J.S., Rhau B., Hermann A., McNally K.A., Zhou C., Gong D., Weiner O.D., Conklin B.R., Onuffer J., Lim W.A. Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal. Proc Natl Acad Sci U S A 2014, 111:5896-5901.
36. Culler S.J., Hoff K.G., Smolke C.D. Reprogramming cellular behavior with RNA controllers responsive to endogenous proteins. Science 2010, 330:1251-1255.
37. Rossger K., Charpin-El-Hamri G., Fussenegger M. A closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice. Nat Commun 2013, 4:2825. 10.1038/ncomms3825.
38. Kemmer C., Gitzinger M., Daoud-El Baba M., Djonov V., Stelling J., Fussenegger M. Self-sufficient control of urate homeostasis in mice by a synthetic circuit. Nat Biotechnol 2010, 28:355-360.
39. Rossger K., Charpin-El Hamri G., Fussenegger M. Reward-based hypertension control by a synthetic brain-dopamine interface. Proc Natl Acad Sci U S A 2013, 110:18150-18155.
40. Ausländer D., Ausländer S., Charpin-El Hamri G., Sedlmayer F., Müller M., Frey O., Hierlemann A., Stelling J., Fussenegger M. A synthetic multifunctional mammalian pH sensor and CO2 transgene-control device. Mol Cell 2014, 55:397-408.
41. Ye H., Charpin-El Hamri G., Zwicky K., Christen M., Folcher M., Fussenegger M. Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome. Proc Natl Acad Sci U S A 2013, 110:141-146.
42. Ye H., Daoud-El Baba M., Peng R.W., Fussenegger M. A synthetic optogenetic transcription device enhances blood-glucose homeostasis in mice. Science 2011, 332:1565-1568.
43. Kirn D.H., Thorne S.H. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009, 9:64-71.
44. Yoo J.W., Irvine D.J., Discher D.E., Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov 2011, 10:521-535.
45. Breitbach C.J., Burke J., Jonker D., Stephenson J., Haas A.R., Chow L.Q., Nieva J., Hwang T.H., Moon A., Patt R., et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011, 477:99-102.
46. Forbes N.S. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer 2010, 10:784-793.
47. Cattaneo R., Miest T., Shashkova E.V., Barry M.A. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008, 6:529-540.
48. Xie Z., Wroblewska L., Prochazka L., Weiss R., Benenson Y. Multi-input RNAi-based logic circuit for identification of specific cancer cells. Science 2011, 333:1307-1311.
49. Park S.J., Park S.H., Cho S., Kim D.M., Lee Y., Ko S.Y., Hong Y., Choy H.E., Min J.J., Park J.O., et al. New paradigm for tumor theranostic methodology using bacteria-based microrobot. Sci Rep 2013, 3:3394. 10.1038/srep03394.
50. Urano Y., Sakabe M., Kosaka N., Ogawa M., Mitsunaga M., Asanuma D., Kamiya M., Young M.R., Nagano T., Choyke P.L., et al. Rapid cancer detection by topically spraying a gamma-glutamyltranspeptidase-activated fluorescent probe. Sci Transl Med 2011, 3. 110ra119.
51. Fujii T., Kamiya M., Urano Y. In vivo imaging of intraperitoneally disseminated tumors in model mice by using activatable fluorescent small-molecular probes for activity of cathepsins. Bioconjugate Chem 2014, 25:1838-1846.
52. Ichikawa Y., Kamiya M., Obata F., Miura M., Terai T., Komatsu T., Ueno T., Hanaoka K., Nagano T., Urano Y. Selective ablation of beta-galactosidase-expressing cells with a rationally designed activatable photosensitizer. Angew Chem Int Ed Engl 2014, 53:6772-6775.
53. Oldenborg P.A., Zheleznyak A., Fang Y.F., Lagenaur C.F., Gresham H.D., Lindberg F.P. Role of CD47 as a marker of self on red blood cells. Science 2000, 288:2051-2054.
54. Rajeeva B.B., Menz R., Zheng Y. Towards rational design of multifunctional theranostic nanoparticles: what barriers do we need to overcome?. Nanomedicine 2014, 9:1767-1770.
55. Ausländer S., Ausländer D., Müller M., Wieland M., Fussenegger M. Programmable single-cell mammalian biocomputers. Nature 2012, 487:123-127.
56. Hsu P.D., Lander E.S., Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014, 157:1262-1278.
57. Onoe H., Okitsu T., Itou A., Kato-Negishi M., Gojo R., Kiriya D., Sato K., Miura S., Iwanaga S., Kuribayashi-Shigetomi K., et al. Metre-long cell-laden microfibres exhibit tissue morphologies and functions. Nat Mater 2013, 12:584-590.
58. Miyamoto T., Razavi S., DeRose R., Inoue T. Synthesizing biomolecule-based Boolean logic gates. ACS Synth Biol 2013, 2:72-82.
59. Stanley S.A., Gagner J.E., Damanpour S., Yoshida M., Dordick J.S., Friedman J.M. Radio-wave heating of iron oxide nanoparticles can regulate plasma glucose in mice. Science 2012, 336:604-608.
60. Stanley S.A., Sauer J., Kane R., Dordick S.J.S., Friedman J.M. Remote regulation of glucose homeostasis in mice using genetically encoded nanoparticles. Nat Med 2015, 21:92-98.
61. Choi M.R., Bardhan R., Stanton-Maxey K.J., Badve S., Nakshatri H., Stantz K.M., Cao N., Halas N.J., Clare S.E. Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse. Cancer Nanotechnol 2012, 3:47-54.
62. Choi M.R., Stanton-Maxey K.J., Stanley J.K., Levin C.S., Bardhan R., Akin D., Badve S., Sturgis J., Robinson J.P., Bashir R., et al. A cellular Trojan horse for delivery of therapeutic nanoparticles into tumors. Nano Lett 2007, 7:3759-3765.
63. Wang C., Sun X., Cheng L., Yin S., Yang G., Li Y., Liu Z. Multifunctional theranostic red blood cells for magnetic-field-enhanced in vivo combination therapy of cancer. Adv Mater 2014, 26:4794-4802.
64. Mooney R., Roma L., Zhao D., Van Haute D., Garcia E., Kim S.U., Annala A.J., Aboody K.S., Berlin J.M. Neural stem cell-mediated intratumoral delivery of gold nanorods improves photothermal therapy. ACS Nano 2014, 8:12450-12460.
65. Aboody K.S., Najbauer J., Metz M.Z., D'Apuzzo M., Gutova M., Annala A.J., Synold T.W., Couture L.A., Blanchard S., Moats R.A., et al. Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. Sci Transl Med 2013, 5. 184ra159.
66. Folcher M., Oesterle S., Zwicky K., Thekkottil T., Heymoz J., Hohmann M., Christen M., Daoud El-Baba M., Buchmann P., Fussenegger M. Mind-controlled transgene expression by a wireless-powered optogenetic designer cell implant. Nat Commun 2014, 5:5392. 10.1038/ncomms6392.